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Abstract: During embryogenesis and development, the fetus obtains oxygen and nutrients 
from the mother through placental microcirculation. The placenta is a distinctive organ that 
develops and differentiates per se, and that organizes fetal growth and maternal condition 
in the entire course of gestation. Several life-threatening diseases during pregnancy, such 
as pregnancy-induced hypertension (PIH) and eclampsia, are closely associated with placental 
dysfunction. Genetic susceptibilities and poor placentation have been investigated intensively to 
understand the pathophysiology of PIH. It is currently thought that “poor placentation hypoth-
esis”, in which extravillous trophoblasts fail to invade sufﬁ  ciently the placental bed, explains 
in part maternal predisposition to this disease. Cumulative studies have suggested that hypoxic 
micromilieu of fetoplacental site, shear stress of uteroplacental blood ﬂ  ow, and aberrantly 
secreted proinﬂ  ammatory substances into maternal circulation synergistically contribute to the 
progression of PIH. For example, soluble form of vascular endothelial growth factor receptor-1 
(sVEGFR-1) and soluble form of CD105 are elevated in circulation of PIH mothers. However, 
it remains to be poorly understood the pathological events in the placenta during the last half 
of gestation as maternal systemic disorders get worse. For better understanding and effective 
therapeutic approaches to PIH, it is important to clarify pathological course of PIH-associated 
changes in the placenta. In this review, current understanding of placental development and 
the pathophysiology of PIH placenta are summarized. In addition, recent ﬁ  ndings of vasoactive 
signalings in PIH and rodent PIH models are discussed.
Keywords: pregnancy-induced hypertension, preeclampsia, placenta, neovascularization, 
intrauterine growth restriction, transgenic mice, renin – angiotensin-system
Introduction
The placenta starts organogenesis in the very early stage of embryogenesis, governs 
fetal growth, and terminates its own fate immediately after delivery. Placental perfusion 
is maintained by two distinct cardiovascular systems, ie, maternal blood ﬂ  ow and fetal 
circulation. Therefore, pathophysiology of the placenta is closely associated with both 
maternal status and fetal development. Among pregnancy-associated complications, 
eclampsia is an emergency condition for both mother and fetus. To prevent the lethal 
disaster, it is mandatory to care properly the patients in preeclamptic condition, 
ie, pregnancy-induced hypertension (PIH). PIH is characterized by blood pressure 
elevation after 20 weeks of gestation that is often accompanied by proteinuria (NHBPEP 
2000). Genetic, immunologic, metabolic susceptibilities and other backgrounds have 
been investigated to understand the pathogenesis of this disease (Hiby et al 2004; 
van Dijk et al 2005; Hu et al 2006; Johnson et al 2007). Several important ﬁ  ndings 
have contributed to our understanding of maternal genetic predisposition, eg, speciﬁ  c 
patterns of genetic variant of angiotensinogen gene and quantitative trait loci on some 
chromosomes including 5q, 10q, and 13q (Morgan et al 1997; Kobashi et al 1999; 
van Dijk et al 2005; Johnson et al 2007). Both background and progression course of 
PIH vary among cases, and it is difﬁ  cult to predict whether the condition is improved Vascular Health and Risk Management 2008:4(6) 1302
Furuya et al
in response to treatment or is aggravated and resulted in 
preterm termination. Currently, the onset of PIH is considered 
to depend not only on a sole or a few pathological events. 
It may rather be triggered by a load of predisposing factors 
that potentially promote circulatory dysfunction (Redman 
and Sargent 2005).
Wide variety of angiogenic molecules and proteolytic 
enzymes play critical roles in the establishment of placen-
tation and development of placental circulatory system 
(Adamson et al 2002; Kharﬁ   et al 2003; Reynolds et al 2005). 
For example, vascular endothelial growth factor (VEGF), 
ﬁ  broblast growth factor (FGF), and placenta growth factor 
(PlGF) are indispensable in the entire course of gestation 
(Reynolds and Redmer 2001; Zygmunt et al 2003). In later 
stages of pregnancy, villous trophoblasts and fetal-side blood 
vessels of terminal villi (or labyrinth in mouse placenta) form 
ﬁ  nely-differentiated vascular network to serve a fetus with 
sufﬁ  cient amounts of oxygen and substances for exponential 
fetal growth (Reynolds et al 2005). The arterial circulation 
in the placenta lacks autonomic innervation and is regulated 
by local signals such as pressure and ﬂ  ow (Myatt 1992). If 
implantation process is not performed successfully, the pla-
centa suffers from insufﬁ  cient perfusion and secretes various 
kinds of proinﬂ  ammatory molecules that damage maternal 
endothelial cells (ECs), and in consequence, vascular resis-
tance is increased that further burdens maternal organs with 
hypertension as well as aggravates fetoplacental milieu 
(Kharﬁ   et al 2003; Karumanchi and Bdolah 2004; Redman 
and Sargent 2005).
It is thought that systemic inﬂ  ammatory response and 
dysfunction of maternal ECs represent the pathological 
scheme of PIH (Granger et al 2001; Karumanchi and Bdolah 
2004; Redman and Sargent 2005). Various proinﬂ  ammatory 
cytokines/peptides including serological markers soluble 
form of VEGF receptor-1 (sVEGFR-1, also named sFlt-1) 
and soluble form of CD105 (sCD105, also named soluble 
form of endoglin) are elevated in PIH mothers, and these 
anti-angiogenic factors are thought to play critical roles in 
maternal ECs-dysfunction (Granger et al 2001; Maynard et al 
2003; Venkatesha et al 2006). On the other hand, it is poorly 
understood the pathological courses of the placenta and 
the mechanisms that lead to intrauterine growth restriction 
(IUGR) of the fetus. With regard to placental dysfunction, 
since very limited examinations are available for pregnant 
patients, the analysis of placental circulation is based mainly 
on Doppler studies and on the pathological investigation 
of terminated placentas (Ohkouchi et al 2000; Parretti 
et al 2003; Kraus et al 2004). The dynamics of vasoactive 
signalings in the placenta during upsurge of blood pressure 
remain enigmatic.
In this review, placental development and proinﬂ  ammatory 
microenvironments of PIH are discussed. First, general 
structure of the placenta in human and mouse is summarized. 
Second, current understanding of pathological events of 
the placenta in PIH is overviewed. Third, the findings 
obtained from PIH model mice are introduced, and possible 
pathological events occurred to fetoplacental vasculature 
under preeclamptic condition are discussed.
Structure of placental vascular 
network
Both in human and mouse, a normal term placenta is 
divided largely into three layers (Figures 1A, 1B): (1) 
Basal plate (maternal surface) and anchoring villi (most 
distal extensions of the primary stem villi) that interact 
directly with maternal endometrium. (2) Terminal villous 
unit (human) or labyrinth (mouse) where gas/nutrients 
exchange is taken place actively. (3) Chorionic plate 
(fetal surface) and stem villi that consist of dense con-
nective tissue containing fetal vessels. Amnion and the 
underling chorion are membranes that cover chorionic 
plate, and the umbilical cord collects chorionic arteries 
and veins on chorionic plate generally in the center part 
(Kraus et al 2004).
Fundamental structure of the placenta is established during 
the ﬁ  rst half of gestation (Reynolds et al 2005). In human 
placenta (Figure 1A), terminal villus unit (tertiary villus that 
stems from secondary villus) is composed mainly of fetal-side 
capillaries lined by ECs, mesenchymal collagen and outlining 
syncytiotrophoblasts. In earlier stages, cytotrophoblasts lie 
beneath syncytiotrophoblasts. As the pregnancy progresses, 
cytotrophoblasts layer become almost undetectable, and 
fetal capillaries are placed in close proximity to intervillous 
maternal circulation, probably for the purpose of efﬁ  cient 
gas/nutrients exchange (Lewis and Benirschke 1997; Kraus 
et al 2004). It is of note, that maternal blood space is lined 
directly by terminally-differentiated syncytiotrophoblasts, 
not by ECs (hemochorial interface) (Rossant and Cross 2001; 
Kraus et al 2004).
Basic architecture of mouse placenta is almost simi-
lar to that of human, but there are some differences at 
microscopic level (Figure 1B). In the “labyrinth”, both 
fetal chorionic branches and maternal blood sinusoids are 
tortuous and exhibit similar dimensions. Blunt-end villi 
are not detectable. Therefore, it is difﬁ  cult to distinguish 
microscopically fetal-side blood flow from that of Vascular Health and Risk Management 2008:4(6) 1303
Pathophysiology of placentation abnormalities in pregnancy-induced hypertension
maternal-side without a help of immunohistochemistry. 
Between fetal and maternal circulatory interface, there 
are three trophoblast layers (trichorial); ie, two syncy-
tiotrophoblast layers surrounding fetal-side ECs, and a 
single mononuclear trophoblast facing to maternal blood 
sinus (Rossant and Cross 2001; Georgiades et al 2002; 
Adamson et al 2002 ).
Fetal weights increase almost twice during the last stage 
(Cunningham et al 1989). On the other hand, the weight of 
the placenta does not increase signiﬁ  cantly in later stages. 
Instead, vascular networks in terminal villi/labyrinth 
become further differentiated and they increase functional 
capacity of fetal-side capillaries as well as of maternal 
blood sinuses (Reynolds et al 2005; Furuya et al 2008) 
(Figure 2). In IUGR, however, terminal villous differen-
tiation is often disturbed, and the truncation of distal villi 
becomes evident (Kraus et al 2004) (Figure 6, center). This 
pathological course is often accompanied by PIH. Under 
hypoxic condition, blood ﬂ  ow of fetal body accumulates 
to the most critical organs such as the brain and the heart. 
This blood redistribution further reduces placental ﬂ  ow and 
increases vascular resistance (Hecher et al 1995).
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Figure 1 Histology of the placenta in human (A) and mouse (B). The photo of whole layer of the placenta is shown in the left. High magnification of each layer is 
shown in the right.
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Figure 2 Development of vascular networks in the labyrinth between E13 and E19. Both fetal vessels (CD31) and maternal blood sinuses (CK) become complicated as 
gestation progresses (Furuya et al 2008).
Abbreviation: CK, cytokeratin.Vascular Health and Risk Management 2008:4(6) 1304
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The early stage of pregnancy: 
Epithelial-endothelial 
transformation
It is well known that during implantation, extravillous 
trophoblasts invade uterine endometrium and also inner 
third of myometrium (Kraus et al 2004; Lyall 2005). To 
establish sufﬁ  cient blood ﬂ  ow from maternal circulation, 
invasive trophoblasts undergo ECs-like specialization. Inva-
sive trophoblasts turn to express some ECs markers such as 
CD31, VE-cadherin, VCAM-1, and αvβ3 integrin (Zhou et al 
1997, 2002). In addition to αvβ3 integrin, these trophoblasts 
up-regulate the expression of α5β1 and α1β1 integrins 
and down-regulate the expression of α6β4 integrin (Lyall 
et al 2001). This process is called “epithelial-endothelial 
transformation” or “pseudo-vasculogenesis” (Damsky and 
Fisher 1998). A similar process of vascular remodeling has 
been reported in cancer neovascularization. In several types 
of malignancies, such as aggressive melanoma, ovarian, 
prostatic, and breast carcinomas, tumor cells themselves 
build blood sinus, known as “tumor vasculogenic mimicry” 
(Maniotis et al 1999; Shirakawa et al 2001; Sood et al 2001; 
Hendrix et al 2003; Sharma et al 2002). The tumor cells 
that form this alternative vascular network express certain 
ECs markers and embryonic vasculogenesis-related mol-
ecules such as VE-cadherin, CD34, and CD105 (Seftor et al 
2002; Hendrix et al 2003). Cancer invasion is destructive 
and disorganized, whereas trophoblasts invasion is ﬁ  nely 
controlled by local proinﬂ  ammatory microenvironments 
under physiological condition. Uterine constituents includ-
ing decidual cells and immune cells govern uteroplacental 
interaction not only to accept “allogenic” cells, but also 
to restrict excessive invasion. Pathological feature of 
impaired epithelial-endothelial transformation in PIH is 
discussed later.
Proinﬂ  ammatory 
microenvironments 
of implantation site
Microenvironments of the uteroplacental junction are crucial 
for the process of implantation and fetal development 
throughout gestation. In response to the upsurge of human 
chorionic gonadotropin (hCG), endometrium undergoes 
decidual change (Perrier d’Hauterive et al 2007), and 
mononuclear cells are accumulated to the decidualized 
endometrium; ie, distinctive population of uterine immune 
cells, called natural killer cells (uNK cells, also named 
decidual natural killer [dNK] cells). uNK cells are CD45+/
CD69+/CD56high/CD16− immune cells that represent the 
majority of leukocytes at the implantation site (Vacca et al 
2006; Moffett and Loke 2006; Moffett and Hiby 2007). 
Although the function of uNK cells is not fully characterized, 
they are thought to play important roles in (1) decidual reac-
tion, (2) remodeling of spiral arteries in the decidua, and (3) 
immune regulation of trophoblasts invasion (Moffett and 
Loke 2006; Pijnenborg et al 2006).
In mouse pregnancy, uNK cells are accumulated to 
implantation site by 10.5 days of gestation (E10.5), and these 
uNK cells inﬁ  ltrate the media of spiral arteries (Adamson et al 
2002). These immune cells contribute to the establishment 
of blood ﬂ  ow from maternal circulation to the placenta in 
cooperation with invasive trophoblasts by remodeling spiral 
arteries (Fig 3). Among various forms of trophoblasts, only 
extravillous trophoblasts express major histocompatibility 
complex (MHC) class I molecules (Moffett and Loke 2006). 
In human pregnancy, these trophoblasts express human 
leukocyte antigens (HLA)-C, HLA-E, and HLA–G, a unique 
repertoire of ligands for uNK cell receptors (King et al 2000a, 
2000b; Moffett and Loke 2006; Moffett and Hiby 2006). 
HLA-A and HLA–B, the classical MHC class I molecules 
with polymorphism that initiate allograft rejection, are not 
expressed in extravillous trophoblasts. Neither MHC class II 
is expressed (Moffett and Loke 2006). It is also of note that 
in fetoplacental site, syncytiotrophoblasts express no MHC 
antigens on cell surface (Moffett and Loke 2006).
PAS
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Figure 3 Remodeling of spiral artery between E10 and E13 in normal mouse pregnancy. 
At E10, PAS-positive uNK cells inﬁ  ltrate the spiral artery. At E13, ECs are replaced by 
CK-positive trophoblasts (Furuya et al 2008).
Abbreviations: PAS, Periodic acid Schiff; uNK cells, uterine natural killer cells; CK, 
cytokeratin.Vascular Health and Risk Management 2008:4(6) 1305
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There are more than one pathways that control uNK cells 
function. uNK cells have both stimulatory and inhibitory 
surface receptors including NKG2 family (CD94), 2B4 
(CD244), and NKp46 (CD335) (King et al 2000a; Vacca et al 
2006). For example, the HLA-E in trophoblasts interacts with 
NKG2A in uNK cells (King et al 2000a), which may explain 
in part the mechanism of suppressed uNK cells cytotoxicity 
against invading trophoblasts. Activating crosstalk between 
invasive trophoblasts and uNK cells is also required. As men-
tioned above, polymorphic MHC class I molecules HLA-A 
and HLA–B are not expressed in extravillous trophoblasts, 
but another classical class I molecule HLA-C is present at 
ﬁ  rst trimester (King et al 2000b). Recent studies on immu-
nogenic background of PIH demonstrated that interaction 
between HLA-C genotypes of trophoblasts and killer-cell 
immunoglobulin-like receptor (KIR)-family of uNK cells 
were implicated in unsuccessful pregnancies (Hiby et al 
2004). Hybi and colleagues (2004) found that the combi-
nation of fetal HLA-C2 haplotype and maternal KIR-AA 
genotype resulted in increased risk of PIH. The mechanism 
is explained as follows; interaction between KIR-A haplo-
type and HLA-C2 haplotype renders strong inhibitory signal 
of uNK cells, whereas KIR-B haplotype has an activating 
receptor for HLA-C haplotype, which increases inﬂ  amma-
tory property of uNK cells (Hiby et al 2004). Taken together, 
ﬁ  ne tuning of pro- and antiinﬂ  ammatory microenvironments 
of uteroplacental site is mediated by the crosstalk between 
maternal-side immune cells and fetal-side invasive tropho-
blasts, and that certain immunogenetic properties may deter-
mine the unfavorable process of pseudovasculogenesis.
Predisposing condition of PIH 
in the early stage of gestation
As mentioned above, it is generally accepted that poor 
placentation is an important predisposing condition for 
the pathophysiology of PIH. The combination of maternal 
KIR-AA genotype in uNK cells and fetal HLA-C2 haplotype 
in extravillous trophoblasts significantly increased the 
susceptibility rate of PIH (Hiby et al 2004), suggesting that a 
failure of proper activation of uNK cells leads to insufﬁ  cient 
trophoblasts invasion. Narrowed blood canals due to poor 
placentation make the placenta hypoxic, and in response, 
a series of proinﬂ  ammatory factors are released from the 
placenta that damage maternal circulatory system. This two 
stage model, ie, poor placentation of early gestational period 
(stage I) and maternal systemic dysfunction in later period 
(stage II), has been widely recognized as a mechanism for the 
development of PIH (Redman and Sargent 2003; Robert and 
Gammill 2005). However, impaired pseudovasculgenesis 
is unlikely to be an exclusive cause of the disease, and 
not a few cases show normal gestational process in spite 
of restricted placental ﬂ  ow, and vice versa (Redman and 
Sargent 2003).
Key molecules implicated 
in the pathophysiology of PIH
There are a wide variety of factors that potentially accelerates 
vasoconstriction of maternal blood vessels. Neurokinin-B, 
a family of peptides tachykinins, was at ﬁ  rst presented to be 
a responsible molecule that causes PIH (Page et al 2000). 
Later studies using large number of samples by different 
groups, however, have demonstrated controversial results 
(Schlembach et al 2003). Currently, it seems not to be fully 
approved the notion that neurokinin-B functions as a caus-
ative agent of PIH. Recent studies by Pal et al provided us 
with a new insight about neurokinin-B in the progression of 
PIH (Pal et al 2006). They demonstrated that neurokinin-B, 
with the help of thromboxane A2 (TXA2)-like molecule, 
down-regulated VEGF, VEGFR-1, and VEGFR-2 in 
cultured ECs, and suppressed angiogenic activities in vitro. 
Since it is known that the imbalance between TXA2 and 
prostacyclin PGI2 is contributed to preeclampsia (Chen 
et al 1993; Mills et al 2001), neurokinin-B/TXA2 axis may 
play some important roles in impaired placental neovascu-
larization. Neurokinin-B is present not only in the maternal 
sera of PIH but also in those of normal pregnancy, and it is 
increased as pregnancy progresses (Sakamoto et al 2003). 
Further investigation is necessary to clarify whether and how 
neurokinin-B/TXA2 suppresses VEGF-mediated signalings 
and contributes to the pathophysiology of PIH in vivo.
Apart from neurokinin-B, sVEGFR-1 has been noted as an 
important serum marker of PIH patients (Maynard et al 2003). 
sVEGFR-1 is an endogenous inhibitor of VEGF and PlGF, 
and excess sVEGFR-1 causes widespread ECs-dysfunction 
by interfering with physiological effects of VEGF and PlGF 
(Kendall et al 1993; Stepan et al 2006). This phenomenon is 
observed not only in PIH patients. In cancer patients under 
antiangiogenic therapies, ie, those who administrated human-
ized monoclonal antibody bevacizumab speciﬁ  cally targeting 
VEGF or several receptor tyrosine kinase (RTK) inhibitors 
targeting VEGF-related pathways, show hypertension, 
proteinuria and edema (Faivre et al 2006; Veronese et al 
2006). The analysis of clinical trials on antiangiogenic 
therapies has shown that these inhibitors disturb more or less 
physiological angiogenesis, hematopoiesis, platelet func-
tion, and so on (Verheul and Pinedo 2007). In PIH patients, Vascular Health and Risk Management 2008:4(6) 1306
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excess sVEGFR-1 seems to be released from the placenta into 
maternal circulation (Cudmore et al 2007).
In addition to sVEGFR-1, several studies conﬁ  rm that sera 
of preeclampsia patients show increased level of sCD105, espe-
cially in severe cases named HELLP syndrome (Hemolysis, 
Elevated Liver enzyme, Low Platelets syndrome) (Venkatesha 
et al 2006). CD105 is a cell surface co-receptor for transforming 
growth factor-1β (TGF-1β) and TGF-3β, and is expressed in 
ECs and syncytiotrophoblasts (Duff et al 2003; Venkatesha et al 
2006). In cardiovascular system, CD105 is thought to regulate 
the expression of endothelial nitric oxide synthase (eNOS) and 
eNOS-dependent vascular tone (Jerkic et al 2004; Santibanez 
et al 2007). In preeclamptic condition, sCD105 probably inhibits 
TGF-1β signalings of vasculature (Venkatesha et al 2006).
Statistical studies suggest that antiangiogenic milieu 
in maternal circulation seems to be arranged 2–3 months 
before preeclamptic symptoms become overt. Increased 
sVEGFR-1 and sCD105, and decreased PlGF and VEGF are 
detectable in the middle of second trimester (17–20 weeks of 
gestation). (Levine et al 2006). Some studies demonstrated 
that sVEGFR-1, as well as VEGF and PlGF, was produced 
in isolated trophoblasts from the placenta in vitro, and the 
level of sVEGFR-1 in culture medium of trophoblasts from 
preeclamptic patients was higher than that from normal 
pregnant women (Ahmad and Ahmed 2004). It is suggested 
that VEGF/PlGF axis in villous trophoblasts that face 
maternal blood ﬂ  ow is responsible for the pathophysiology 
of PIH. Under other pathophysiological conditions such as 
diabetic retinopathy and cancer, hypoxia generally stimulates 
angiogenic signalings, eg, hypoxia-inducible factor (HIF)-
1α-mediated transcriptional cascade of proangiogenic 
molecules including VEGF (Semenza 2003). Currently, it 
remains poorly understood why hypoxic placenta produces 
the molecules that suppress angiogenesis in preeclampsia. It is 
also a subject for future study whether sVEGFR-1 and sCD105 
are secreted directly in response to hypoxia or whether some 
other important regulators, including mechanical stress and 
vasoactive G protein-coupled receptor (GPCR) cascades, also 
accelerate the secretion of these anti-angiogenic molecules 
from the placenta. Recent studies have elucidated the 
implication of angiotensin II-mediated signalings in excessive 
production of sVEGFR-1 from the placenta in preeclampsia, 
which will be discussed later.
Implication of renin-angiotensin 
system (RAS) in PIH
Renin-angiotensin system (RAS) is one of mastermind 
signalings that control blood pressure, and this signaling 
cascade participates not only in vasoconstriction but also in 
a wide variety of homeostatic activities (Lavoie and Sigmund 
2003; Paul et al 2006). The expression of renin mRNA was 
detected in human decidua, basal placenta, macrophages, 
chorioamniotic membrane and vascular smooth muscle cells 
(VSMCs) (Lentz et al 1989; Jikihara et al 1995; Kalenga 
et al 1996; Morgan et al 1998). Angiotensin II receptor 
type 1 (AT1) was shown to be localized both in villous and 
extravillous trophoblasts and this AT1 responds to exog-
enously administrated angiotensin II (Li et al 1998; Cooper 
et al 1999; Zhou et al 2007). Functionally, local RAS is 
thought to participate in the regulation of uteroplacental blood 
ﬂ  ow, prostaglandin synthesis, estradiol secretion, and so on 
(Kalenga et al 1995; Li et al 1998; Nielsen et al 2000).
The circulating level of angiotensin II increases as the 
pregnancy progresses (Zheng et al 2005). It was revealed that 
in the circulation of PIH mothers RAS was not increased but 
rather decreased (Hanssens et al 1991). Thus RAS has once 
been considered to be unrelated to the pathophysiology of 
PIH (Hanssens et al 1991; Kalenga et al 1996). On the other 
hand, it is accepted as a classical knowledge that vascular 
sensitivities to angiotensin II are elevated in preeclamptic 
women (Gant et al 1973). The mechanism of elevated 
angiotensin II sensitivity in PIH remained unanswered for 
a few decades.
AbdAlla and colleagues (2001) investigated the pres-
ence of AT1-bradykinin B2 heterodimers in the platelets 
and omental vessels of pregnant women. They demonstrated 
that bradykinin B2 protein level increased in preeclamptic 
patients, and that AT1-bradykinin B2 heterodimers acceler-
ated GPCR signal transduction. The results strongly suggest 
that angiotensin II cascades are enhanced in preeclamptic 
patients in part by an increase of bradykinin B2 protein 
which forms heterodimer with AT1 in vivo. The heterodi-
mer formation seems to be present not only in maternal 
vasculature but also in the placental constituents, because 
immunohistochemical stainings of bradykinin B2 were 
reported to be enhanced in the extravillous trophoblasts of 
preeclampsia cases (Corthorn et al 2006). It is likely that 
AT1-mediated signalings are augmented by bradykinin B2 
at uteroplacental interface which may aggravate fetoplacental 
microcirculation.
There is an alternative pathway that potentially enhances 
AT1-mediated vasoconstriction in preeclampsia. Agonistic 
autoimmune antibody against AT1 (AT1-AA) was detected 
in the sera of preeclamptic women (Wallukat et al 1999). 
Although later studies have revealed that AT1-AA is also 
detectable in normotensive pregnant women with IUGR and Vascular Health and Risk Management 2008:4(6) 1307
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those without signiﬁ  cant complications (Walther et al 2005), 
the ﬁ  nding provides us with a new insight into preeclampsia 
in the context of autoimmune disease. In a recent study, AT1 
gene was shown to be elevated in the decidua of preeclamptic 
mothers and AT1-AA was increased in the fetal sera of 
preeclampsia cases (Herse et al 2007). These results suggest 
that AT1 cascades in uteroplacental junction are aberrantly 
activated and that this antibody crosses the placenta and 
disturb fetal cardiovascular system in preeclampsia. A very 
recent study by Zhou and colleagues (2008) demonstrated that 
AT1-AA from preeclamptic women accelerated sVEGFR-1 
secretion via AT1 expressed in pregnant mice in vivo, and 
also in human placental villous explants and immortalized 
human trophoblast cell line in vitro. This study shed a light 
on the long-standing question; whether and how RAS is 
implicated in the pathophysiology of PIH. They found that 
enhanced AT1 cascades disturbed VEGF/PlGF axis thorough 
calcineurin and nuclear factor of activated T-cells (NFAT) 
(Zhou et al 2008). The mechanism of vascular dysfunction 
in PIH which involve sVEGFR-1 and AT1 cascades awaits 
further investigation with special attention, ie, angiogenic 
crosstalk between GPCR and RTK (Hobson et al 2001; 
Waters et al 2006; Furuya and Yonemitsu 2008). Impaired 
neovascularization under excess AT1 signalings has been 
demonstrated in the experiments using PIH model mouse, 
which will be discussed later.
Preeclamptic mouse based
on excessive RAS
Takimoto and colleagues (1996) generated mice by mating 
females expressing human angiotensinogen (hAG) with 
males expressing human renin (hRN), and named them 
Pregnancy-Associated Hypertension mice (PAH mice) 
(Figure 4A). In PAH mice, maternal blood pressure starts 
elevating from 13 days of gestation (E13) until delivery 
(E19–20) (Figure 4A). Systolic blood pressure at E19 in 
PAH mother reaches 160 mmHg whereas that in normal 
pregnant mouse remains around 100 mmHg (Takimoto et al 
1996). Blood pressure returns to normal level by 3 days after 
delivery. This elevation is attributable to the generation of 
excessive angiotensin I, ie, the precursor of angiotensin 
II, in the maternal circulation through hRN secretion from 
fetal side (Takimoto et al 1996). In addition to hypertension, 
PAH mother shows proteinuria, cardiac hypertrophy and 
often convulsions. The fetus at term in PAH pregnancy 
shows severe IUGR, and the mean body weight of PAH 
fetus at E19 is about 65% of that of wild type (WT) fetus 
(Takimoto et al 1996; Saito et al 2004; Takimoto-Onishi 
et al 2005) (Figure 4B). Both biological and physiological 
data demonstrated that RAS-mediated maternal hypertension 
beginning in the second half of gestation led PAH mother 
to the pathological condition that satisﬁ  ed the criteria of 
PIH. Similar model was generated in rats (Bohlender et al 
2000). The hAG-transgenic female rat mated with hRN-
transgenic male rat developed hypertension abruptly 10 days 
before delivery, and sustained this status (approximately 
160 mmHg) until delivery. The course of hypertension in 
this model rat was different from that in PAH mouse; PAH 
mother showed linear elevation of blood pressure from E13 
until delivery.
We observed that uNK cells inﬁ  ltrated the spiral arteries 
sufﬁ  ciently and that trophoblasts replaced spiral arteries in the 
uteroplacental site of PAH placenta earlier than E13 (Furuya 
et al 2008). The results suggest that epithelial-endothelial 
transformation is probably taken place properly in PAH as 
well as in normal one. Interestingly, in a recent study using 
the placenta of preeclamptic rat as mentioned above, endo-
vascular trophoblast invasion in hypertensive transgenic 
rat was also evident, and it was shown that the invasion 
was rather deeper than that in normal rat (Geusens et al 
2008). This ﬁ  nding in rat model might reﬂ  ect the variability 
of species-speciﬁ  c regulation of local RAS. The precise 
mechanism of enhanced trophoblast invasion needs further 
investigation.
In spite of sufﬁ  cient invasion at an early stage, maternal 
circulatory sVEGFR-1 in PAH mouse is significantly 
increased at E19. The ﬁ  nding was consistent with that of 
another group, in which infusion of angiotensin II signiﬁ  cantly 
increased circulating levels of sVEGFR-1 in pregnant mice 
(Zhou et al 2007). Zhou and colleagues (2008) have further 
shown that the inhibition of AT1 signalings by administration 
of losartan or FK506 resulted in reduced sVEGFR-1. Taken 
together, it is highly suggested that maternal sVEGFR-1 
can be elevated not only by poor placentation but also by 
AT1 activation in which angiotensin II, AT1-AA, and AT1-
bradykinin B2 heterodimers are potentially implicated.
AT1 plays critical roles
in the development of IUGR
Increased angiotensin II is generally not the case in human pre-
eclampsia. Therefore, in the context of  “pathogenesis”, PAH mice 
may not be relevant to human PIH. On the other hand, as mentioned 
above, it is now widely recognized the aberrantly activated AT1 
signalings in PIH patients. To clarify the signiﬁ  cance of AT1 
signalings in PAH, Saito et al investigated the effects of AT1 
blockade in this model (Saito et al 2004). They generated hAG+/+ Vascular Health and Risk Management 2008:4(6) 1308
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mother that lacked AT1a (hAG+/+/mAT1a−/−). In hAG+/+/mAT1a−/−
female, hypertension did not occur when mated with hRN+/+ male. 
Furthermore, fetal condition was signiﬁ  cantly improved (Figure 
5). Administration of AT1-antagonists to hAG+/+ mother also 
improved both maternal and fetal conditions, supporting the notion 
that AT1-mediated signalings play critical roles in PAH model 
(Saito et al 2004). The study clearly proved that AT1-mediated 
signalings in maternal circulation contributed to the pathophysiol-
ogy of fetal IUGR.
Although AT1 and VEGFRs play pivotal roles in the 
pathophysiology of IUGR, it should be noted that vessel 
receptors are activated not only by biochemical substances. 
Signalings in vascular cells are also potentially controlled 
by shear stress and hemodynamic load (Li et al 1999; 
Kalluri 2003). Mechanical force is known to act on several 
sensors including platelet-derived growth factor receptor 
(PDGFR)-β, integrins and ion channels in the vascular cells, 
and to modulate cellular morphology (Li and Xu 2000). 
Thus, it is suggested that in PIH patients, once blood pressure 
starts elevating, shear stress per se accelerates unfavorable 
signalings in maternal circulation which contributes to 
placental dysfunction and IUGR development.
The process of impaired 
neovascularization after the onset 
of hypertension
Pathological examination of human PIH placenta reveals 
diffuse ﬁ  brin deposition and acute atherosis in uteroplacental 
sites, ie, mural ﬁ  brinoid necrosis of spiral arteries (Figure 6, 
left). With regard to fetoplacental circulatory unit, termi-
nal villi are poorly differentiated, so called distal villous 
hypoplasia (Figure 6, center). Syncytial knots, ie, aggrega-
tion of syncytiotrophoblastic nuclei, are also noted (Figure 6, 
right). It is generally thought that such changes in PIH reﬂ  ect 
placental hypoxia due to shallow invasion of extravillous tro-
phoblasts at initial stage. However, it has not been answered 
whether acute atherosis and impaired neovascularization 
also occur by other predisposing factors, eg, accelerated 
AT1 signaling.
As mentioned above, PAH placenta shows normal-looking 
pseudovasculogenesis at initial stage; ie, sufﬁ  cient uNK cells 
inﬁ  ltration and appropriate trophoblasts invasion (Furuya 
et al 2008). It may not be surprising because at this stage the 
level of hRN produced from the placenta is not enough to 
act on hAG of maternal circulation (Takimoto et al 1996). 
We investigated placental pathology, and found signiﬁ  cant 
atherosis with apoptotic change in uteroplacental site of PAH 
at E19. Time course analysis showed impaired fetoplacental 
vascular development and maturation after the onset of 
hypertension. Microvessel densities were signiﬁ  cantly low, 
and fetal-derived ECs were lacking for appropriate pericytes 
coverage and basement membrane support (Figure 4B) 
(Furuya et al 2008). These ﬁ  ndings indicate that placental 
neovascularization is potentially suppressed under mater-
nal hypertension without the history of poor placentation. 
In the analysis of vasoactive molecules, some vasoactive 
genes were down-regulated within 24 hrs after the onset of 
WT mAT-1a-/- mAT-1a -/-,
hRN hRN hRN
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Figure 5 The effect of mAT1a blockade in PAH model. PAH fetus is shown to be signiﬁ  cantly small in size (center right). In the fetus from hANG+/+mAT-1a−/− female mated 
with hRN+/+ male, the growth is markedly improved (right) (Saito et al 2004).
Abbreviations: hANG, human angiotensinogen; hRN, human renin; mAT-1a, mouse angiotensin II receptor type 1a receptor; WT, wild type; PAH, pregnancy-associated 
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hypertension. Then the molecules that mediate ECs-pericytes 
interaction were hampered at the middle stage of hyperten-
sion (Furuya et al 2008). These results suggest that the fate 
of pathological neovascularization might be designated by 
early responsive genes and that following disturbance of the 
signalings for vessel maturation might result in abnormal 
fetoplacental vasculature in the terminal stage. Further studies 
are necessary to clarify whether the series of angiogenic dis-
turbances are taken place in time-dependent manner one after 
another, or the dysfunction of each molecule is determined by 
the level of shear stress and/or AT1 signaling strength.
Conclusions and future prospects
As described in this review, AT1-mediated signalings 
are aberrantly activated in many, if not all, PIH cases. It 
is necessary to understand the roles of AT1 in pregnancy 
complications in a wide range of view. Various GPCRs 
including AT1 are reported to transactivate epidermal 
growth factor receptor (EGFR) in vitro (Prenzel et al 
1999; Olivares-Reyes et al 2005), thus it might not be surpris-
ing that AT1 and other GPCRs potentially cross-talk with 
VEGF/PlGF-mediated RTK signalings and contribute to 
sVEGFR-1 production (Furuya et al 2005; Milstien and Spie-
gel 2006; Dorsam and Gutkind 2007; Zhou et al 2008). Some 
GPCRs such as neurokinin-B and endothelin-1 are likely to 
play critical roles in the pathophysiology of PIH (Page et al 
2000; Ajne et al 2003), thus they may also be involved in 
RTK-mediated neovascularization in the placenta.
Currently, the pathophysiology of PIH should also be 
investigated from artiﬁ  cial immunogenic milieu that had 
been unexpected in old era. Because of improved therapeu-
tic approaches to infertility, backgrounds of PIH and IUGR 
have become more and more complicated. Obstetricians may 
face PIH cases in which the third genetic factor is involved, 
ie, gestational surrogacy and oocyte donation pregnancy. 
It is reported that the risk of PIH is increased up to 30% 
in oocyte donation pregnancy (Salha et al 1999). Although 
maternal conditions vary among cases, it is very likely that 
the frequency of PIH in the women after infertility treatment 
will be increased.
For better understanding and management of PIH, it is 
necessary to investigate not only human cases but also rodent 
PIH models in which the mechanism of placental dysfunction 
and IUGR under maternal hypertension can be monitored in 
detail. It is also desirable to analyze therapeutic effects of 
targeting molecules involved in various angiogenic pathways 
of the placenta. If the mechanism of placental dysfunction 
in PIH and other IUGR-associated complications is fully 
elucidated, it will certainly provide more precise disease-
speciﬁ  c strategies, and contribute to more effective and safer 
therapies in future.
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